Abstract
Breast cancer is by far the most frequent cancer in women, worldwide and ranks third overall when both sexes are considered together. For many malignancies, serum tumor markers play an important role in patient management. MUC-1 glycoprotein based serum markers (CA15-3 and CA 27.29) are assays approved by the US Food and Drug Administration for monitoring patients with advanced breast cancer. Potential applications include early detection of recurrent disease and monitoring treatment efficacy in patients with advanced disease. While retrospective data regarding the role of CA27.29 correlates well with progression and treatment of metastatic breast cancer, a multicenter prospective study to further assess the role of CA 27.29 for monitoring of locally advanced disease is warranted.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 29-30 |
| Number of pages | 2 |
| Journal | Open Breast Cancer Journal |
| Volume | 3 |
| DOIs | |
| State | Published - 2011 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
All Science Journal Classification (ASJC) codes
- Oncology
- Cancer Research
Fingerprint
Dive into the research topics of 'Clinical utility of monitoring serial CA 27.29 in patients with different stage of breast cancer'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver